GlyHealth-IBD is the most advanced of our disease-specific GlyHealth variants. It is a prognostic and predictive biomarker of inflammatory bowel disease (IBD).The test is being designed to support clinical decision-making by gastroenterologists caring for IBD patients and as a complementary biomarker to enhance clinical trials for anti-inflammatory drugs for IBD.

The glycomics patterns we measure in GlyHealth-IBD are early-warning, sub-clinical, prodromal signals of future Inflammatory Bowel Disease flares.

Preliminary studies on over 400 patients showed that GlyHealth-IBD can, from a small (0.2ml) sample of blood, reliably measure:

  1. The severity of an IBD patient’s disease now,
  2. The likely future course of their disease and
  3. The likelihood they would need future treatment escalation up to 18 months from the time of testing.